Trials / Terminated
TerminatedNCT01203943
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.
Conditions
- Idiopathic Pulmonary Fibrosis
- Pulmonary Fibrosis
- Fibrosis
- Interstitial Lung Disease
- Lung Diseases, Interstitial
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-930 | CC-930 50 mg PO daily up to 56 weeks beginning on Day 1 |
| OTHER | Placebo | Placebo |
| DRUG | CC-930 | CC-930 100 mg PO daily up to 56 weeks beginning on Day 1 |
| DRUG | CC-930 | C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1 |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-01-31
- Completion
- 2012-08-24
- First posted
- 2010-09-17
- Last updated
- 2019-11-19
Locations
22 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01203943. Inclusion in this directory is not an endorsement.